Flow Cytometry:B-lymphoid lineage assignment: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
Line 9: | Line 9: | ||
<div style="width: | <div style="width: 95%; border: 1px solid black; font-size:100%"> | ||
{| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0" | {| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0" | ||
!colspan="2" <span style="font-size:90%; font-color:navy; style="text-align: left; border: 1px solid black; background:pale gray">|'''Requirements to assign B-lymphoid lineage'''</br></span> | !colspan="2" <span style="font-size:90%; font-color:navy; style="text-align: left; border: 1px solid black; background:pale gray">|'''Requirements to assign B-lymphoid lineage'''</br></span> |
Revision as of 20:16, 5 January 2024
Requirements to assign B-lymphoid lineage
| |
---|---|
Marker option 1 | |
Required Strong expression of CD19 Required also ONE of either: CD10, CD22, or CD79a (surface or cytoplasmic) |
To meet the definition of "strong" the expression, the intensity of CD19 must exceed that of 50% of normal B lymphocytes |
Marker option 2 | |
Required Weak expression of CD19 Required also TWO of either: CD10, CD22, or CD79a (surface or cytoplasmic) |
To meet the definition of "weak" the expression intensity of CD19 must be less than that of 50% of normal B lymphocytes |
Marker option 3 | |
CD19 is not expressed In this rare occurrence then requires THREE of either: CD10, CD22, or CD79a (surface or cytoplasmic) |
This is a rare occurrence and should be carefully considered |
Notes on interpretation of B-lineage
CD19 is considered by WHO to have high but not complete specificity for B-lineage. Its’ use requires the intensity of expression to be considered: “strong” CD19 expression should exceed 50% of the level seen on normal B progenitors in at least some of the leukaemic cells, while weaker CD19 expression has lower specificity and requires stronger additional evidence of B-lineage commitment (see Table above). Note also: (1) CD79a has frequent expression in T-LL/LBL, so should not be used to suggest B-lineage if that disorder is considered. (2) PAX5 identified by immunohistochemistry has a low evidence base in MPAL diagnosis so should be interpreted with caustion. (3) In the absence of CD19 expression, B-lineage may still be assigned if three other B antigens are expressed.